What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
Jiaxin Yin(Wuhan University), Bicheng Zhang(University of Electronic Science and Technology of China), Jiazhuo Tang(Wuhan University), Yuxiao Song(Wuhan University)
Cited by 36
Related Papers
Clinical characteristics of 82 cases of death from COVID-19
|PLoS ONE|2020|594
Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19
|Frontiers in Molecular Biosciences|2020|497
Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019
|Clinical Infectious Diseases|2020|458
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
|Frontiers in Immunology|2020|256
Clinical characteristics of 82 death cases with COVID-19
|medRxiv|2020|249